The National Medical Products Administration recently announced that according to the "Measures for the Classification Management of Prescription Drugs and Non prescription Drugs (Trial)" (formerly Order No. 10 of the National Medical Products Administration), after being organized by the National Medical Products Administration for verification and review, Zhongsheng Tablets and Qiangshen Tablets will be converted from prescription drugs to over-the-counter drugs. The user manual of Zhongsheng tablets shows that the main functions of this product are clearing heat and detoxifying, promoting blood circulation and cooling blood, and reducing inflammation and pain. Used for upper respiratory tract infections, acute and chronic pharyngitis, acute tonsillitis, and other conditions; The instruction manual of Qiangshen tablets shows that the main function of this product is to tonify the kidney and fill in essence, and to nourish qi and strengthen yang. Used for lower back pain and nocturia caused by yin and yang deficiency. The announcement states that relevant drug marketing license holders are required to file the revised instructions with the provincial drug regulatory department in accordance with the "Drug Registration Management Measures" and other relevant regulations before February 20, 2025, and promptly notify relevant medical institutions, drug trading enterprises, and other units of the revised instructions. Other contents of the instructions for over-the-counter drugs beyond those specified in the template shall be executed in accordance with the original approval certificate. If the drug label involves relevant content, it should be revised together. Drugs produced from the date of supplementary application filing shall not continue to use the original drug instructions. (Lai Xin She)